Red Arrow Therapeutics is a Japanese biotech company that focuses on developing innovative therapies for cancer. Their lead product candidate, RA-001, is a polymer micelle loaded with IL-12 that activates in response to the tumor's pH, releasing fully active IL-12 to enhance immunotherapy. RA-001 has shown strong anti-tumor immunity in pre-clinical data and has demonstrated high efficacy both as a standalone treatment and in combination with immune checkpoint inhibitors. The company aims to maximize drug potency while minimizing toxicity, offering a next-generation approach to cancer treatment.